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Abstract 
Background: The relationship between plasma angiopoietin-like protein 3 (ANGPTL3), 
and lipoprotein lipase (LPL) activity and hepatic triglyceride lipase (HTGL) activity 
has not been investigated in the metabolism of remnant lipoproteins and HDL. 
Methods: Angiopoietin-like protein-3 (ANGPTL3), LPL activity, HTGL activity, 
remnant lipoproteins (RLP-C & RLP-TG), small dense LDL-Cholesterol (sd LDL-C) 
were measured in 20 overweight and obese subjects in the fasting and postprandial 
state. 
Results: Plasma TG, RLP-C, RLP-TG and sd LDL-C were inversely correlated with LPL 
activity both in the fasting and postprandial state, but not correlated with HTGL 
activity and ANGPTL3. However, plasma HDL-C was positively correlated with LPL 
activity both in the fasting and postprandial state, while inversely correlated with 
HTGL activity. ANGPTL3 was inversely correlated with HTGL activity both in the 
fasting and postprandial state, but not correlated with LPL activity. 
.Conclusion: Plasma remnant lipoproteins and sdLDL-C were inversely correlated with 
LPL activity but not correlated with HTGL activity and ANGPTL3, indicating that LPL, 
but not HTGL, plays a major role in the metabolism of remnant lipoproteins including 
small dense LDL. However, HDL-C was inversely correlated with HTGL activity and 
positively correlated with ANGPTL3, indicating that HTGL plays a major role in HDL 
metabolism but not remnant lipoprotein metabolism. These findings suggest that 
ANGPTL3 is strongly associated with the inhibition of HTGL activity and regulates 
HDL metabolism, but not associated with the inhibition of LPL activity for the 
metabolism of remnant lipoproteins in human plasma.. 
 
１. Introduction 
The regulation of TG-rich lipoprotein metabolism by angiopietin-like protein 3 
(ANGPTL3) was first reported by Koishi et al (1) in KK obese mouse which is known to 
have abnormally high levels of plasma insulin (hyperinsulinemia), glucose 
(hyperglycemia) and lipids (hyperlipidemia). They observed abnormally low plasma 
lipid level in one strain (KK/San) which carried the defected hypolipidemia (hypl) locus 
in the middle of chromosome 4 encoded as ANGPTL3 gene. Over expression of 
ANGPTL3 or intravenous injection of the purified protein in KK/San mice elicited an 
increase in circulating plasma lipid levels, especially TG. These data suggested that 
ANGPTL3 regulates TG-rich lipoprotein metabolism in mice through inhibiting LPL 
and HTGL activities (2, 3). Therefore, we first paid attention to ANGPTL3 as an 
inhibitor of LPL activity associated with remnant lipoprotein metabolism in humans.  
However, Shimamura et al (4 ) and we (5) recently found that plasma ANGPTL3 levels 
were not correlated with TG levels in human plasma unlike in mice and was shown to 
be more strongly associated with HDL metabolism. Furthermore, we found that 
ANGPTL3 was more frequently associated with increased HDL-C rather than CETP 
deficient cases in plasma of Japanese hyperalphalipoproteinemic subjects, but not 
associated with TG levels (5). 
From these results, we investigated if ANGPTL3 really regulate TG-rich lipoprotein 
metabolism through inhibiting LPL and HTGL activities in human plasma as in mice. 
LPL has been known to hydrolyze chylomicrons (CM) and very low density lipoproteins 
(VLDL) to form their remnants in human plasma (6,7), and HTGL has been known to 
hydrolyze β-VLDL or IDL to form small, dense LDL (sd LDL) (8). HTGL is also known 
to hydrolyze TG in LDL and HDL, especially to hydrolyze HDL2 to form HDL3 (9, 10). 
Therefore, we speculated that if ANGPTL3 regulate both LPL and HTGL activity to 
form remnant lipoproteins and sd LDL, the inverse correlations between ANGPTL3 
concentration and LPL and HTGL activities could be found in human plasma. 
Here, we have analyzed the concentrations of ANGPTL3, TG, remnant lipoproteins, sd 
LD-C and HDL-C in human plasma, together with LPL and HTGL activity recently 
developed by Imamura et al (11, 12). For the analysis of LPL and HTGL activities, we 
used post-heparin plasma in the fasting and postprandial state to measure the lipase 
activities associated with remnant lipoprotein metabolism. For small dense LDL 
analysis, we have used small dense LDL-cholesterol (sd LDL-C) assay which is a 
quantitative assay based on the density rather than particle size (13). The detection 
method of LPL activity, HTGL activity and sd LDL-C we used in this study are newly 
developed methods in Japan and different from the previous radioisotope methods 
reported on these interactions. The analysis was conducted in plasma of 20 overweight 
and obese volunteers who were generally healthy and susceptible to be postprandial 
remnant hyperlipoproteinemia, appropriate for the study of interactions among lipase 
activities and other parameters. Taken together, we have investigated the role of 
ANGPTL3 on LPL and HTGL activities in remnant lipoproteins, small dense LDL and 
HDL metabolism in humans and discussed the differences between the mouse studies 
reported previously (1-3 ).. 
 2. Materials and methods 
2.1 Study subjects 
The study in healthy volunteers who were overweight and obese and were susceptible to 
be postprandial remnant hyperlipoproteinemia was performed in men (n=10) and 
post-menopausal women (n=10), age 40-71, BMI 25-35 at the University of California, 
Davis (Table 1). The UC Davis Institutional Review Board approved the experimental 
protocol, and subjects provided informed consent to participate in the study. All the 
volunteers were generally healthy and did not take any medications during this study. 
Bloods were provided to analyze for this study from the fructose and glucose comparison 
study reported by Stanhope et al (14). 
Fasting blood samples were collected at 8:00 h in the morning and postprandial blood 
samples were collected at 20:00 h in the evening on the same day. During the day, the 
standardized foods were provided as breakfast, lunch and dinner to all the volunteers 
The energy content of the meals was based on each subject’s energy requirement as 
determined by the Mifflin equation (15). Each volunteer participated in fasting and 
postprandial pre and post-heparin blood collections on two different days over a period 
of 12 weeks. Therefore, 20 volunteers under different conditions at each time were 
withdrawn two fasting bloods and two postprandial bloods for analysis on different days 
before and after fructose and glucose treatment. All the data were pooled for a total of 
40 pairs of fasting and postprandial time points.  
 
2.2. Measurements of lipids, lipoproteins, ANGPTL3 and lipase activities. 
The plasma samples for the measurement of TC, TG, HDL-C, LDL-C, RLP-C, RLP-TG 
and sd LDL-C were withdrawn immediately before heparin infusion and kept frozen at 
-80℃ until analysis. As LPL and HTGL activities were not detectable in pre-heparin 
plasma (12), all the lipase activities in this study were determined in post-heparin 
plasma. Post-heparin plasma in 15 min after intravenous injection of 50 units of 
heparin/kg body weight (BW) was withdrawn for the assay of LPL, HTGL activity and 
ANGPTL3. Plasma samples were kept frozen at -80℃ until analysis. TC and TG 
concentration were determined enzymatically. LDL-C and HDL-C concentration was 
measured using a homogenous method (Kyowa Medex, Tokyo). Glucose and insulin 
were determined by PolyChem (Polymedco, NY). RLP-C and RLP-TG were determined 
by immunoseparation method (JIMRO II, Otsuka, Tokyo) (16). Small dense LDL-C was 
determined by the method of Hirano et al (13 ). ANGPTL3 was measured by the ELISA 
method by Moon et al (5). LPL and HTGL activities were measured by the method of 
Imamura et al (12) 
 
2.3 Statistical Analysis 
Data were analyzed with Dr. SPSS II (SPSS, Chicago, IL). 
Quantitative variables are reported as mean ± S.D values. The statistical significance of 
difference was determined by Mann-Whitney U-test. The correlation between variables 







3.1 Plasma lipids, lipoproteins, LPL, HTGL activity and ANGPTL3 analyses in the 
fasting and postprandial state. 
The fasting and postprandial plasma levels of lipids and lipoproteins in 20 volunteers 
recruited in UC Davis, CA are shown in Table 2. Mean total cholesterol and LDL-C 
levels were within normal range and did not change between the fasting and 
postprandial state. Triglycerides, RLP-C, RLP-TG levels were significantly elevated and 
sd LDL-C and HDL-C significantly decreased in the postprandial state. LPL and HTGL 
activities did not change significantly. ANGPTL3 levels decreased significantly in the 
postprandial plasma compared with in the fasting plasma. Single regression analysis of 
these parameters in 20 volunteers was shown in Table 3. ANGPTL3 did not correlate 
significantly with TG and remnant lipoproteins in the fasting and postprandial state, 
while strongly and inversely correlated with HDL-C. 
  
3.2. TG correlations between LPL activity, HTGL activity and ANGPTL3 
Plasma TG concentration was inversely correlated with LPL activity (Figure 1A) both in 
the fasting ( r=-0.63, P<0.001) and postprandial (r=-0.68, P<0.001) state respectively, 
while no correlation was found with HTGL activity (Figure 1B) both in the fasting 
(r=0.04, NS) and postprandial (r=0.18, NS) state. No correlation was found with 
ANGPTL3 both in the fating and postprandial state (Figure 1C, Table 3). 
 
3.2. RLP-C correlations between LPL activity, HTGL activity and ANGPTL3 
RLP-C was inversely correlated with LPL activity (Figure 2A) both in the fasting 
( r=-0.42, P<0.001) and postprandial (r=-0.58, P<0.001) state respectively, while no 
correlation was found with HTGL activity both in the fasting and postprandial state 
(Figure 2B). No correlation was found with ANGPTL3 in the fasting and postprandial 
state (Table 3)． 
 
3.3. RLP-TG correlations between LPL activity, HTGL activity and ANGPTL3 
 RLP-TG was inversely correlated with LPL activity(Figure 2 C) both in the fasting 
( r=-0.47, P<0.01) and postprandial (r=-0.68, P<0.001) state respectively, and positively 
correlated with HTGL activity in the postprandial state (r=0.33, p=0.03) (Figure 2 D)
（Not correlated in the fasting state, but slightly correlated in the postprandial state）. 
The positive correlation between RLP-TG and HTGL activity means that HTGL does 
not hydrolyze RLP-TG. No correlation was found with ANGPTL3 in the fasting and 
postprandial state(Table 3)． 
 
3.4 Correlations of sd LDL-C between LPL activity, HTGL activity and ANGPTL3 
Table 3 shows that sd LDL-C was inversely correlated with LPL activity, both in the 
fasting (r=-0.43, p<0.001) and postprandial (r=-0.35, P<0.05) state respectively, while no 
correlation was found with HTGL activity both in the fasting and postprandial state. No 
correlation was found with ANGPTL3 in the fasting and postprandial state.  
Furthermore, sd LDL-C with TG, RLP-C and RLP-TG were positively correlated both in 
the fasting (r=0.55 P<0.001; r=0.28, NS; r=0.38, P<0.01 ) and in the postprandial 
(r=0.38 P<0.01; r=0.33, P<0.05; r=0.27, P<0.05) state, respectively. Although sdLDL-C 
levels significantly decreased, and RLP-C and RLP-TG levels significantly increased in 
the postprandial state (Table 2), positive correlations were shown among them. 
 
3.5. HDL-C correlations between LPL activity, HTGL activity and ANGPTL3 
 HDL-C was positively correlated with LPL activity in the fasting (0.38, P<0.01) and 
postprandial (r=0.45, P<0.01) (Figure 3A) state and inversely correlated with HTGL in 
the fasting (r=-0.49, p<0.001) and in the postprandial state (r=-0.50, P<0.01) (Figure 3 
B). HDL-C was positively correlated with ANGPTL3 in the fasting (r=0.36, p<0.05) but 
not in the postprandial (r=0.32, NS) state (Figure 3C).  
 
3.6. ANGPTL3 correlations between LPL activity and HTGL activity 
As the plasma concentrations of ANGPTL3 were not affected by heparin infusion, 
ANGPTL3 was determined in post-heparin plasma together with LPL and HTGL 
activities. ANGPTL3 concentration was not correlated with LPL activity (Figure 4A) 
both in the fasting (r=-0.21, NS) and postprandial (r=-0.20, NS) state, however, 
inversely correlated with HTGL (Figure 4 B) both in the fasting (r=-0.50, p<0.001) and 
postprandial (r=-0.31, p<0.05). These results strongly suggest that ANGPTL3 is not an 











Remnant lipoproteins have been recognized as the metabolized products of TG-rich 
lipoproteins by lipoprotein lipase and hepatic triglyceride lipase. ANGPTL3 was 
considered to be the inhibitor of both LPL and HTGL activity and to cause the delayed 
metabolism of TG-rich lipoproteins in animal studies (1-3). However, the interactive 
roles of ANGPTL3 on LPL and HTGL activity in humans have not been reported yet. 
In this manuscript, we have shown the correlation between the lipase activities and its 
inhibitor ANGPTL3 in remnant lipoprotein and HDL metabolism in human plasma, 
using newly developed LPL, HTGL activity assay method (12). Especially, the previous 
investigators have all used radioisotope method for LPL and HTGL activity assay 
developed by Brunzell et al (17) in their studies, which are labor-intensive and known to 
typically have within and between run coefficients of variation of over 10 %. Our 
analyses of LPL and HTGL activity were carried with a high through-put activity assay 
performed on an automated analyzer, with coefficients of variation of 3% or less (11, 12). 
Therefore it was possible to measure a large number of plasma samples at one time to 
compare the correlations among these parameters.  
The study was conducted in the fasting and postprandial state in 20 healthy volunteers 
to investigate the relationship between lipase activities and ANGPTL3, mainly in 
remnant lipoprotein metabolism including small dense LDL.  
ANGPTL3 was found as an inhibitor for both LPL and HTGL in mice (1-3).  
ANGPTL3-null mice revealed markedly low plasma lipid concentrations, especially 
plasma TG concentration with a normal, high-fat, or high calorie diet. Fujimoto et al (3) 
reported that lipoprotein lipase and hepatic lipase activities in the post-heparin plasma 
of ANGPTL3-null mice were 1.57 folds and 1.42 fold higher than those of wild-type mice, 
respectively. When ANGPTL3 were over expressed or injected to mice, plasma TG and 
NEFA levels increased significantly within a few hours, indicating the inhibition of LPL 
and HTGL activity by ANGPTL3 (3). Therefore, ANGPTL3 has been recognized as an 
inhibitor for both LPL and HTGL in mice and associated with the metabolism of 
remnant lipoproteins. ANGPTL3 and TG concentrations in plasma were highly 
correlated in mice (1-3), however it was not observed in human plasma as reported by 
Shimamura et al (4) and by us (5).  
In this study, we found that the plasma remnant lipoprotein and sd LDL-C 
concentrations were inversely correlated with LPL activities. Unexpectedly, HTGL 
activities were not correlated with remnant lipoproteins and sdLDL-C in human plasma, 
which may be different from the previous literatures (17-21). HTGL has been reported 
to have a role to hydrolyze small VLDL remnants or intermediate density lipoproteins 
(IDL) to form sd LDL (20). However, we could not find correlation between HTGL 
activity and sd LDL-C concentration as well as remnant lipoproteins. Previously, higher 
HTGL activity was reported to be correlated with higher small dense LDL concentration 
in plasma (18). Therefore, it has been considered acceptable that inhibition of HTGL 
activity decreases the formation of small dense LDL and reduces the risk of 
cardiovascular disease, The determination of small dense LDL in previous studies has 
been conducted by size or charge separation methods described as pattern A and B (22). 
However, we used a new detection method of small dense LDL in this study, which 
determines the cholesterol concentration quantitatively in small dense LDL fraction 
isolated by the density and particle size separation developed by Hirono et al (13). Using 
the quantitative sdLDL-C assay method, we could not find any correlation between 
HTGL activity and sd LDL-C concentration, although we found strong inverse 
correlation between LPL activity and sd LDL-C in the same cases, similar with the 
correlation between LPL activity and RLPs. As it has been known that small dense LDL 
is positively correlated with remnant lipoproteins in plasma (23), these data stands on 
the same line that remnant lipoproteins are the precursor of sd LDL and metabolized in 
the same pathway by LPL,. However unexpectedly, it was not correlated with HTGL 
activity as reported previously (17-21). 
From these data, HTGL seems not to play a significant role in the metabolic pathway of 
remnant lipoproteins unlike reported previously, but mainly plays a role in HDL 
metabolism in humans (18). Namely, ANGPTL3 showed a significant inverse 
correlation with HTGL activity as shown in Figure 4 B and positively correlated with 
HDL-C concentration (4, 5). Furthermore, Shimamura et al (4 )  and Jin et al (24 ) 
emphasized the role of ANGPTL3 on the inhibition of endothelial lipase (EL) in HDL 
metabolism. In this manuscript, we have first shown that ANGPTL3 is strongly 
associated with HTGL activity and HDL metabolism in human plasma. The inhibition 
of EL by ANGPTL3 in human plasma is still unknown because of the difficulty of 
measuring EL activity. 
An interesting possibility of different role of ANGPTL3 on LPL activity in humans and 
mice is the cleavage of ANGPTL3 in plasma. The cleavage of ANGPTL3 by proprotein 
convertase is reported to be important for the activation of ANGPTL3 to inhibit LPL 
activity (24). Ono et al (25) reported that a majority of ANGPTL3 detected in mouse 
plasma was cleaved fragments of N-terminal ANGPTL3 (17-165), while only a small 
amount of N-terminal fragments with a majority of full length ANGPTL3 were detected 
in human plasma. They speculated that full length ANGPTL3 is not able to inhibit LPL 
in vivo unless it is cleaved to N-terminal fragment. Therefore, full length ANGPTL3 
which present mainly in human plasma may not play a role for inhibiting LPL activity. 
We are now studying the role of full length and N-terminal fragment of ANGPTL3 on 
lipase activities in human plasma.  
Probucol is known to decrease plasma HDL-C levels significantly. As a new mechanism 
of probucol on HDL-C reduction in addition to the previously known mechanisms (26), 
Miida et al have shown that probucol treatment significantly decreased serum 
ANGPTL3 concentration (27). Decreasing ANGPTL3 may enhance HTGL or endothelial 
lipase (EL) activity (4) and decreased HDL-C significantly. Therefore, probucol could 
increase HTGL activity through the decrease of ANGPTL3. Homma et al (28) reported 
that probucol markedly reduced plasma HDL2 levels. The reduction rates of TC, TG and 
apo A-I levels in HDL2 were 43.0%, 43.6% and 47.0%. These results suggested the 
increased HTGL activity by probucol treatment, possibly through the decrease of 
ANGPTL3. These findings also suggest that ANGPTL3 does not inhibit LPL activity in 
human plasma, however it inhibits HTGL or EL activity to increase HDL-C. As plasma 
ANGPTL3 levels reflect HTGL activity inversely and HDL-C positively, ANGPTL3 
could be a therapeutic target for raising HDL-C levels like CETP. Because HTGL 
activity assay requires heparin infusion before blood withdrawal, ANGPTL3 may take 
place of HTGL activity assay as a therapeutic target, which is not required 
heparin-infusion for analysis. 
As for LPL inhibitors associated with remnant lipoprotein metabolism, ANGPTL4 
reported by Kersten et al (29) or recently discovered 
glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (30) 
may inhibit LPL activity directly in human plasma and increase the plasma 
concentration of remnant lipoproteins, independent from ANGPTL3. 
 In conclusion, ANGPTL3 was not associated with LPL activity and remnant 
lipoproteins in human plasma unlike in mice, however ANGPTL3 was strongly 
associated with HTGL activity. Therefore, ANGPTL3 may be strongly associated with 
HDL metabolism by inhibiting HTGL activity, but not associated with remnant 
lipoprotein metabolism in humans.  
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Figure 1.  TG correlations between LPL activity, HTGL activity and ANGPTL3 in 20 
subjects. 
 Plasma TG was inversely correlated with LPL activity (A). No correlation was found 
between TG and HTGL activity (B). No correlation was found between TG and 
ANGPTL3 (C). Eighty plots reflect the total of 4 plots in each volunteer in the fasting 
(n=40) (open circle) and postprandial (n=40) (closed circle) state, before and after 
glucose and fructose treatment study during 12 weeks. 
 
Figure 2.  RLP-C and RLP-TG correlations between LPL and HTGL activity in 20 
subjects  
Plasma RLP-C was inversely correlated with LPL activity (A). No correlation was found 
between RLP-C and HTGL activity (B). Plasma RLP-TG was inversely correlated with 
LPL activity (C) and positively correlated with ANGPTL3 in the postprandial state(D).  
Eighty plots reflect the total of 4 plots in each volunteer in the fasting (n=40) (closed 
circle) and postprandial (n=40) (open circle) states, before and after glucose and fructose 
treatment study during 12 weeks. 
 
Figure 3   HDL-C correlations between LPL activity, HTGL activity and ANGPTL3 in 
20 subjects. 
 HDL-C was positively correlated with LPL activity (A) and inversely correlated with 
HTGL (B). HDL-C was positively correlated with ANGPTL3 in the fasting state (C). 
Eighty plots reflect the total of 4 plots in each volunteer in the fasting (n=40) (open 
circle) and postprandial (n=40) (closed circle) states, before and after glucose and 
fructose treatment study during 12 weeks. 
 
Figure 4.  ANGPTL3 correlations between LPL and HTGL activity in 20 subjects. 
ANGPTL3 concentration was not correlated with LPL activity (A) both in the fasting 
and postprandial state, however inversely correlated with HTGL (B) both in the fasting 
(r=-0.50, p<0.001) and postprandial (r=-0.31, p<0.05). Eighty plots reflect the total of 4 
plots in each volunteer in the fasting (n=40) (open circle) and postprandial (n=40) 












olic Blood Pressure(㎜ 120±2 117±2
tolic Blood Pressure(㎜ 77±1 76±2
T-Chol(mg/dl) 182±12 197±16





Body Fat (%) 29±1 41±2
101±2 91.5±6aist Circumference(cm
 
The values presented are mean ±ＳＤ 
 
  
Table 3. Single Regression Analysis of the parameters in the fasting and postprandial state. 
 
Fasting 
  r 
   TG RLP-C RLP-TG sdLDL-C HDL-C LPL HTGL ANGPTL3 
TG - 0.718 *** 0.882 *** 0.564 *** -0.374 ** -0.429 ** -0.057 0.153
RLP-C 0.718 *** - 0.911 *** 0.279 -0.194 -0.274 -0.010 0.198
RLP-TG 0.882 *** 0.911 *** - 0.428 ** -0.229 -0.246 0.018 0.158
sdLDL-C 0.564 ***  0.279 0.428 ** - -0.355 ** -0.221 -0.101 -0.117
HDL-C -0.374 ** -0.194 -0.229 -0.355 ** - 0.331 * -0.488 *** 0.361 **
LPL -0.429 ** -0.274 * -0.246 -0.221 0.331 * - 0.076 -0.129
HTGL -0.057 -0.010 0.018 -0.101 -0.488 *** 0.076 - -0.497 ***
ANGPTL3    0.153   0.198   0.158  -0.117   0.361 **  -0.129  -0.497 *** - 
Postprandial 
  r 
   TG RLP-C RLP-TG sdLDL-C HDL-C LPL HTGL ANGPTL3 
TG - 0.863 *** 0.954 *** 0.435 ** -0.419 ** -0.384 ** 0.094 0.000 
RLP-C 0.863 *** - 0.860 *** 0.363 ** -0.319 * -0.400 ** -0.053 0.218 * 
RLP-TG 0.954 *** 0.860 *** - 0.330 * -0.422 ** -0.418 ** 0.238 -0.044 
sdLDL-C 0.435 ** 0.363 ** 0.330 * - -0.299 -0.209 -0.195 -0.116 
HDL-C -0.419 ** -0.319 ** -0.422 ** -0.299 * - 0.349 * -0.469 *** 0.243 
LPL -0.384 ** -0.400 ** -0.418 ** -0.209 0.349 * - -0.193 -0.268 *
HTGL 0.094 -0.053 0.238 -0.195 -0.469 *** -0.193 - -0.254 
ANGPTL3    0.000   0.218   -0.044  -0.116   0.243    -0.268 * -0.254   - 
 
*; p < 0.05, **; p < 0.01, ***; p < 0.001             
 




